240,891 Shares in Solventum Co. (NYSE:SOLV) Purchased by Diamond Hill Capital Management Inc.

Diamond Hill Capital Management Inc. acquired a new position in Solventum Co. (NYSE:SOLV) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 240,891 shares of the company’s stock, valued at approximately $15,913,000. Diamond Hill Capital Management Inc. owned about 0.14% of Solventum at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Modus Advisors LLC purchased a new stake in shares of Solventum during the fourth quarter worth $25,000. Stonebridge Financial Group LLC purchased a new stake in Solventum during the 4th quarter valued at about $26,000. True Wealth Design LLC grew its stake in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new stake in Solventum in the 4th quarter valued at about $32,000. Finally, Prospera Private Wealth LLC purchased a new position in Solventum in the 3rd quarter worth approximately $35,000.

Solventum Stock Up 2.8 %

Shares of NYSE SOLV opened at $74.31 on Friday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business’s 50 day moving average is $74.52 and its two-hundred day moving average is $71.07. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm has a market cap of $12.85 billion and a price-to-earnings ratio of 27.02.

Wall Street Analyst Weigh In

SOLV has been the subject of several recent research reports. Morgan Stanley increased their price target on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. The Goldman Sachs Group raised their target price on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Mizuho raised their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Finally, Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, Solventum currently has an average rating of “Hold” and an average target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.